by
Javed Butler;
Gregg C. Fonarow;
Michael R. Zile;
Carolyn S. Lam;
Lothar Roessig;
Erik B. Schelbert;
Sanjiv J. Shah;
Ali Ahmed;
Robert O. Bonow;
John GF Cleland;
Robert J. Cody;
Ovidiu Chioncel;
Sean P. Collins;
Preston Dunnmon;
Gerasimos Filippatos;
Martin P. Lefkowitz;
Catherine N. Marti;
John J. McMurray;
Frank Misselwitz;
Vasiliki Georgiopoulou
The burden of heart failure with preserved ejection fraction (HFpEF) is considerable and is projected to worsen. To date, there are no approved therapies available for reducing mortality or hospitalizations for these patients. The pathophysiology of HFpEF is complex and includes alterations in cardiac structure and function, systemic and pulmonary vascular abnormalities, end-organ involvement, and comorbidities. There remain major gaps in our understanding of HFpEF pathophysiology. To facilitate a discussion of how to proceed effectively in future with development of therapies for HFpEF, a meeting was facilitated by the Food and Drug Administration and included representatives from academia, industry, and regulatory agencies. This document summarizes the proceedings from this meeting.